|
Session 110
Poster Abstracts
Resistance to Integrase Inhibitors
Monday, 1-2:30 pm
Poster Hall |
| 614 |
Mutational Mapping on the Integrase-3’-proc-cDNA Complex Suggests 4 Different Mechanisms of Resistance to Raltegravir and Explains the High-level Resistance of the Most Important Mutants Selected in vivo
A Vout1, F Christ1, D Vogelaers2, C Verhofstede2, M De Maeyer1, Z Debyser1, and Linos Vandekerckhove*2
1Katholieke Univ Leuven, Belgium and 2Univ Hosp Ghent, Belgium |
| 615 |
The G140S Integrase Mutation from Raltegravir-resistant Patients Rescues HIV-1 Integration Defect Induced by the Resistance Mutation Q148H
Olivier Delelis*1, I Malet2, L Na1, L Tchertanov1, V Calvez2, A-G Marcelin2, F Subra1, E Deprez1, and J-F Mouscadet1
1LBPA CNRS UMR8113, Cachan, France and 2Hopital Pitie Salpetriere, UPMC Univ Paris 06, Paris, France |
| 616 |
Evaluation by Allele-specific Real-time Polymerase Chain Reaction of the Presence of Q148H, Q148R, and N155H Minority Variants at Baseline of a Raltegravir-based Regimen
Charlotte Charpentier*1,2, C Piketty3, P Tisserand1, L Bélec1,2, D Laureillard3, M Karmochkine3, A Si-Mohamed1, and L Weiss2,3
1Laboratoire de Virologie, Hôpital Européen Georges Pompidou, Paris, France; 2Faculté de Médecine Paris Descartes, Paris, France; and 3Service d`Immunologie Clinique, Hôpital Européen Georges Pompidou, Paris, France |
| 617 |
Selective Advantage Curves Explain Evolution of Raltegravir Resistance Genotypes in vivo
R Quercia, E Dam, and François Clavel*
Inserm U552, IUH, Hopital Saint-Louis, Paris, France |
618
 |
Quasispecies Variant Dynamics during Emergence of Resistance to Raltegravir in HIV-1-infected Patients
I Malet1, O Delelis2, C Soulie1, M Wirden1, S Lambert-Niclot1, G Peytavin3, J-F Mouscadet2, C Katlama1, V Calvez1, and Anne-Genevieve Marcelin*1
1Hosp Pitie-Salpetriere, Paris, France; 2LBPA, CNRS, Ecole Normale Superieure de Cachan, France; and 3Hopital Bichat-Claude Bernard, Paris, France |
619
|
Clonal Analysis of Raltegravir-resistant Patterns Including Mutations at Positions 143 and 155 in the HIV-1 Integrase
G Anies1, D Da Silva1, P Recordon-Pinson1,2, S Reigadas1,2, L Wittkop3, D Neau1,2, P Morlat1,2, H Fleury1,2, and Bernard Masquelier*1,2
1université Victor Segalen, Bordeaux, France; 2Ctr Hosp Univ Bordeaux, France; and 3INSERM U 897, Bordeaux, France |
| 620 |
Longitudinal Phenotypic Analysis of Raltegravir-resistant Viruses during Virologic Failure
S Fransen1, M Karmochkine2, W Huang1, L Weiss2,3, C Petropoulos1, and Charlotte Charpentier*3,4
1Monogram Biosciences, South San Francisco CA, USA; 2Service d`Immunologie Clinique, Hôpital Européen Georges Pompidou, Paris, France; 3Faculté de Médecine Paris Descartes, Paris, France; and 4Laboratoire de Virologie, Hôpital Européen Georges Pompidou, Paris, France |
| 621 |
Long-term Evolution of Integrase Resistance during Failure of Integrase Inhibitor-based ART
H Hatano1, Harry Lampiris*1, S Gupta2, S Fransen2, W Huang2, R Hoh1, J Martin1, C Petropoulos2, and S Deeks1
1Univ of California, San Francisco, US and 2Monogram Biosci, South San Francisco, CA, US |
622
|
Raltegravir Interruption Has No Effect on HIV-1 RNA Plasmatic Level in Patients Harboring Viruses with Resistance-associated Mutations to This Drug
Marc Wirden*1, A Simon1, L Schneider1, I Malet1, R Tubiana1, G Peytavin2, A-G Marcelin1, M-A Valantin1, C Katlama1, and V Calvez1
1Hosp Pitie-Salpetriere, Paris, France and 2Hosp Bichat, Paris, France |
|
